Astellas mulls options after Gilead's CV offer
This article was originally published in Scrip
The battle for CV Therapeutics may well not be over. Although Astellas had made no announcement by the end of Tokyo trading on March 13th, there was speculation that the Japanese firm could raise its bid for the US firm in the wake of Gilead Sciences' $1.4 billion white knight offer.
You may also be interested in...
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.
New long-term clinical data with Takeda’s dengue vaccine contender show a durable response against all four serotypes and support the dosing regimen in an ongoing pivotal study.